Comparative Pharmacology
Head-to-head clinical analysis: DOXYCHEL versus PANMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOXYCHEL versus PANMYCIN.
DOXYCHEL vs PANMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the mRNA-ribosome complex.
Tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from attaching to the A site.
100 mg orally or intravenously every 12 hours on day 1, then 100 mg once daily. For severe infections, continue 100 mg every 12 hours.
250-500 mg PO q6h or 500 mg to 1 g IV q6h; maximum 4 g/day
None Documented
None Documented
12-22 hours (mean ~16 hours); prolonged in severe hepatic impairment (up to 30 hours).
Terminal elimination half-life is 6-8 hours in patients with normal renal function. Half-life is significantly prolonged (up to 80 hours) in anuria, requiring dose adjustment.
Renal (20-30%), biliary/fecal (40-60%), with significant enterohepatic circulation; nonrenal elimination accounts for about 70%.
Primarily renal excretion of unchanged drug via glomerular filtration; 80-90% recovered in urine within 24 hours. Biliary/fecal excretion accounts for <5%.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic